Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

ANCA-associated Vasculitis Clinical Trial

Official title:

A Prospective, Open-label, Controlled, Single Center Clinical Study of the Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05965284
• Other study ID #: CSTAR-K2374
• Status: Recruiting
• Phase: Phase 4
• Start date: March 9, 2023
• Est. completion date: December 31, 2026

Study information

• Verified date: July 2023
• Source: Chinese SLE Treatment And Research Group
• Contact: Yunjiao Yang, M.D.
• Phone: +86-13671313079
• Email: yangyunjiao81[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to compare the remission rate of patients treated with Telitacicept combined with azathioprine and azathioprine alone in remission-maintenance treatment of AAV.

Description:

Background: The basic theme of AAV is relapse and remission. The maintenance therapy of AAV aimed to reduce or prevent relapse is very challenge. Although many medications have been used for the maintenance of AAV, Telitacicept (a BAFF/APRIL dual-target-inhibitor, which has been proved to be effect in treatment of SLE) has not been studied yet. One study tested the efficacy of Belimumab in the maintenance therapy for AAV. When taken Rituximab as remission-induction treatment, no relapse was observed. However, the sample size of this study is small, and the Belimumab, as a BAFF inhibitor, was not been proved to have effect on APRIL. Many experiences have been accumulated about the efficacy and safety of Telitacicept in Chinese patients with rheumatic diseases. But there is no study to show its effectiveness in the reduction of the relapse of AAV in China. In this study, we add Telitacicept to azathioprine in maintain treatment in AAV patients who receive Rituximab as remission-induction treatment, to compare the relapse rates of Telitacicept combining azathioprine and azathioprine alone in maintenance therapy of AAV. Objectives: To compare the relapse rates of Telitacicept combining azathioprine and azathioprine alone in maintenance treatment of AAV. Study Design: This is a prospective, randomized, open-label, control, pilot study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Patients age 18 to 65 years, both genders can be included.

2. Patients who are newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis must fulfill the 2022 ACR/EULAR classification criteria of GPA or MPA.

3. Patients who are in complete remission after combined treatment with glucocorticoids and Rituximab. Remission is defined as a Birmingham Vasculitis Activity Score (BVAS version 3) of 0. And the daily dosage of prednisone are no more than 10mg (or equivalent).

4. Patients have to be ANCA-positive at diagnosis or during the course of their disease.

Exclusion Criteria:

1. Patients with TPMT gene mutation.

2. Patients who had been treated with either AZA but relapsed in the past.

3. Patients who had been treated with either AZA but had to stop due to adverse events or intolerance.

4. Patients who have planned for pregnancy in next 1.5 years.

5. Patients with severe liver dysfunction(defined as the 2-folds elevation of normal upper limit or Child grade III), heart failure or ESRD(eGFR<30ml/min).

6. Patients with uncontrolled sever hypertension, diabetes, active bacteria or fungal infection;

7. Patients with active hepatitis virus infection as well as patients who have active mycobacteria infection;

8. Patients who had other autoimmune diseases.

9. Patients with malignancy.

10. Patients who are not eligible according to the judge of the principal investigators or site investigators.

Related Conditions & MeSH terms

• ANCA-associated Vasculitis
• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
• Maintenance Therapy
• Vasculitis

Intervention

Drug:
• Azathioprine
All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.
• Telitacicept
Patient will be treated with Telitacicept (Taiai the commercial name) 160 mg every week subcutaneously for 12 months

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese SLE Treatment And Research Group

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The time of first relapse during 12 months follow-up of two groups	The time from baseline to first relapse(re-appearance of disease with a BVAS >0) of patients during 12 months follow-up of two groups	from inclusion to the end of the study, 12 months in total
Secondary	The percentage of patients with severe relapse at months 12	The percentage of patients with severe relapse (re-appearance or worsening of disease with a BVAS =6 and involvement of at least one major organ, a life-threatening manifestation, or both) at months 12	from inclusion to the end of the study, 12 months in total
Secondary	The percentage of patients with moderate relapse at months 12	The percentage of patients with moderate relapse (re-appearance or worsening of disease with a BVAS =3 without involvement of major organ or life-threatening manifestation) at months 12	from inclusion to the end of the study, 12 months in total
Secondary	The percentage of patients with mild relapse at months 12	The percentage of patients with mild relapse (re-appearance or worsening of disease with a 0 < BVAS < 3 without involvement of major organ or life-threatening manifestation) at months 12	from inclusion to the end of the study, 12 months in total
Secondary	The percentage of patients with sustained remission at months 12	The percentage of patients with sustained remission (BVAS =0 without dosage increase of glucocorticoid) at months 12	from inclusion to the end of the study, 12 months in total
Secondary	The rate of adverse events	The rate of adverse events and their severity (Severe events were defined as the adverse events of grade 3 or 4, deaths caused by any cause, cancers, side effects that necessitate hospitalization) in both two groups during the study period.	from inclusion to the end of the study, 12 months in total
Secondary	The percentage of patients who progress to ESRD	The percentage of patients who progress to ESRD at the end of the study	from inclusion to the end of the study, 12 months in total
Secondary	The rate of complication of AAV	The rate of complication of AAV in both treatment groups during 12 months of the study period.	from inclusion to the end of the study, 12 months in total